University of California San Francisco

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 24
  1. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy.
    O'Keefe TJ, Wallace AM| | PubMed
  2. Bilateral mastectomy associated with higher breast cancer mortality among patients with estrogen receptor positive progesterone receptor negative localized breast cancer.
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  3. Accurate genome-wide genotyping from archival tissue to explore the contribution of common genetic variants to pre-cancer outcomes.
    Nachmanson D, Pagadala M, Steward J, Cheung C, Bruce LK, Lee NQ, O'Keefe TJ, Lin GY, Hasteh F, Morris GP, Carter H, Harismendy O| | PubMed
  4. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
    Zhou M, Wang S, Wan N, Yuan S, Hu X, Zhou W, Qing B, Liu M, Sun W, Fan P, Wang J, Cao H, Xu H, Dai B, Tang P, Qian L, Zhao X, Xiao J, Zhou H, Hu J, Ding L, Tripodi D, Zdenkowski N, O'Keefe TJ, Sanchez AM, Chen L, Zhang P, Xu F| | PubMed
  5. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence.
    O'Keefe TJ, Chau H, Harismendy O, Wallace AM| | PubMed
  6. Histopathological growth distribution of ductal carcinoma in situ: tumor size is not "one size fits all".
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  7. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O| | PubMed
  8. Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  9. Archives of Breast Cancer
    O’Keefe, T., Harismendy, O., Esserman, L., Wallace, A.M.| | UCSF Research Profile
  10. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O| | PubMed
24
View all 24 Publications
MOST RECENT PUBLICATIONS FROM A TOTAL OF 24
  1. Using half-hitch knots to uncouple surgical knot security and loop tautness
    O'Keefe TJ, Perkins LA, Guajardo I, Adams LM, Cosman BC, Ardill WD, Potenza BM| | UCSF Research Profile
  2. Using Millimeter Measurements and Force Gauges to Test the Security of Knots Tied by Residents Before and After Watching Online Didactic Videos
    O'Keefe TJ, Perkins LA, Austin J, Oviedo P, Khan S, Guajardo I, Adams LA, Cosman BC, Ardill WD, Potenza BP.| | UCSF Research Profile
  3. Bilateral Mastectomy vs Lumpectomy and Breast Cancer Mortality Risk.
    O'Keefe TJ, Alvarado MD, Esserman LJ| | PubMed
  4. The Gordian knot of it he will unloose”: Lessons learned from studies of half-hitch surgical knots and implications for practicing surgeons: A systematic review
    O'Keefe, TJ, Lake C, Perkins LA, Perez SA, Guajardo I, Carlson Hyman S, Adams LA, Cosman BC, Ardill WD, Potenza BM| | UCSF Research Profile
  5. Modernizing Surgical Quality: A Novel Approach to Improving Detection of Surgical Site Infections in the Veteran Population.
    Perkins L, O'Keefe T, Ardill W, Potenza B| | PubMed
  6. Distance of Biopsy-Confirmed High-Risk Breast Lesion from Concurrently Identified Breast Malignancy Associated with Risk of Carcinoma at the High-Risk Lesion Site.
    Le J, O'Keefe TJ, Khan S, Grossi SM, Choi HY, Ojeda-Fournier H, Armani A, Wallace AM, Blair SL| | PubMed
  7. Duration of Endocrine Treatment for DCIS impacts second events: Insights from a large cohort of cases at two academic medical centers.
    O'Keefe T, Yau C, Iaconetti E, Jeong E, Brabham C, Kim P, McGuire J, Griffin A, Wallace A, Esserman L, Harismendy O, Hirst G| | PubMed
  8. Reply to: "Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns.
    Goldhaber N, O'Keefe T, Blair S| | PubMed
  9. Glucocorticoid receptor regulates the epithelial-mesenchymal transition process through GR/ZEB1/E-cad and is involved in breast cancer endocrine drug resistance-a bioinformatics analysis.
    Tang Y, Ma J, Zhang H, Ma W, Ma W, O'Keefe TJ, Pratap A, Yamada A, Wang L, Gao Y, Zhang Q, Zhao W| | PubMed
  10. Is Choosing Wisely Wise for Lobular Carcinoma in Patients Over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns.
    Goldhaber NH, O'Keefe T, Kang J, Douglas S, Blair SL| | PubMed
  11. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy.
    O'Keefe TJ, Wallace AM| | PubMed
  12. Bilateral mastectomy associated with higher breast cancer mortality among patients with estrogen receptor positive progesterone receptor negative localized breast cancer.
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  13. Accurate genome-wide genotyping from archival tissue to explore the contribution of common genetic variants to pre-cancer outcomes.
    Nachmanson D, Pagadala M, Steward J, Cheung C, Bruce LK, Lee NQ, O'Keefe TJ, Lin GY, Hasteh F, Morris GP, Carter H, Harismendy O| | PubMed
  14. Efficacy and safety of neoadjuvant pertuzumab plus trastuzumab in combination with chemotherapy regimen in Chinese patients with HER2-positive early breast cancer: a real-world retrospective multi-center cohort study.
    Zhou M, Wang S, Wan N, Yuan S, Hu X, Zhou W, Qing B, Liu M, Sun W, Fan P, Wang J, Cao H, Xu H, Dai B, Tang P, Qian L, Zhao X, Xiao J, Zhou H, Hu J, Ding L, Tripodi D, Zdenkowski N, O'Keefe TJ, Sanchez AM, Chen L, Zhang P, Xu F| | PubMed
  15. Risk factors for breast cancer mortality after ductal carcinoma in situ diagnosis differ from those for invasive recurrence.
    O'Keefe TJ, Chau H, Harismendy O, Wallace AM| | PubMed
  16. Histopathological growth distribution of ductal carcinoma in situ: tumor size is not "one size fits all".
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  17. The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ.
    Nachmanson D, Officer A, Mori H, Gordon J, Evans MF, Steward J, Yao H, O'Keefe T, Hasteh F, Stein GS, Jepsen K, Weaver DL, Hirst GL, Sprague BL, Esserman LJ, Borowsky AD, Stein JL, Harismendy O| | PubMed
  18. Large and diffuse ductal carcinoma in situ: potentially lethal subtypes of "preinvasive" disease.
    O'Keefe TJ, Harismendy O, Wallace AM| | PubMed
  19. Archives of Breast Cancer
    O’Keefe, T., Harismendy, O., Esserman, L., Wallace, A.M.| | UCSF Research Profile
  20. Mutational profiling of micro-dissected pre-malignant lesions from archived specimens.
    Nachmanson D, Steward J, Yao H, Officer A, Jeong E, O'Keefe TJ, Hasteh F, Jepsen K, Hirst GL, Esserman LJ, Borowsky AD, Harismendy O| | PubMed
  21. Ductal carcinoma in situ in patients younger than 30 years: differences in adjuvant endocrine therapy and outcomes.
    Halasz SR, O'Keefe T, Wallace AM, Blair SL| | PubMed
  22. Surveillance, Epidemiology, and End Results program underestimates breast cancer-specific mortality after ductal carcinoma in situ diagnosis.
    O'Keefe TJ, Wallace AM| | PubMed
  23. HER2-Overexpressing Ductal Carcinoma In Situ Associated with Increased Risk of Ipsilateral Invasive Recurrence, Receptor Discordance with Recurrence.
    O'Keefe TJ, Blair SL, Hosseini A, Harismendy O, Wallace AM| | PubMed
  24. Classical and Quantum Gravity
    Harms J, Acernese F, Barone F, Bartos I, Beker M, Brand JFJ, Christensen N, Coughlin M, DeSalvo R, Dorsher S, Heise J, Kandhasamy S, Mandic V, Marka S, Muller G, Naticchioni L, O'Keefe TJ, Rabeling DS, Sajeva A, Trancynger T, Wand V.| | UCSF Research Profile